OPEN ACCESS
NIJBAS
Publications 2025
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES (NIJBAS)

Volume 7 Issue 2 Page 60-65, 2026

https://doi.org/10.59298/NIJBAS/2026/7.2.6065

Metabolic Toxicity in Chronic Disease: The Overlooked Role of Oxidative Stress and Inflammation

Zakaria Ali

Department of Pharmacy Kampala International University Uganda
Email:ali.zakaria@studwc.kiu.ac.ug

ABSTRACT

Metabolic toxicity is an increasingly recognized contributor to the pathogenesis and progression of chronic diseases, including diabetes, cardiovascular disorders, neurodegenerative conditions, cancer, and chronic kidney disease. It arises from sustained metabolic dysregulation that leads to the accumulation of toxic intermediates, impaired energy homeostasis, and cellular dysfunction. Central to this process are oxidative stress and chronic low-grade inflammation, which interact in a self-perpetuating cycle to damage biomolecules, disrupt signaling pathways, and impair tissue function. Despite extensive research on metabolic abnormalities in chronic disease, the integrated roles of oxidative stress and inflammation in driving metabolic toxicity remain underappreciated. This review examines the mechanistic links between metabolic dysregulation, reactive oxygen species generation, inflammatory signaling, and cellular toxicity. We discuss how oxidative stress and inflammation contribute to mitochondrial dysfunction, insulin resistance, endothelial damage, and organ-specific pathology across major chronic diseases. Understanding metabolic toxicity as a redox- and inflammation-driven process offers new insights into disease mechanisms and highlights potential therapeutic strategies aimed at restoring metabolic and redox homeostasis rather than targeting isolated disease endpoints.

Keywords: Metabolic toxicity, Oxidative stress, Chronic inflammation, Mitochondrial dysfunction, Chronic disease

INTRODUCTION

Chronic diseases represent the leading cause of morbidity and mortality worldwide, accounting for a substantial proportion of healthcare burden and reduced quality of life [1]. Conditions such as diabetes mellitus, cardiovascular disease, neurodegenerative disorders, chronic kidney disease, and metabolic syndrome share common pathological features, including persistent metabolic imbalance, cellular stress, and progressive organ dysfunction [2]. Traditionally, these diseases have been studied within organ-specific frameworks, focusing on glucose dysregulation, lipid abnormalities, or immune dysfunction in isolation [3]. However, growing evidence suggests that a unifying mechanism underlying many chronic diseases is metabolic toxicity.

Metabolic toxicity refers to cellular and tissue damage caused by prolonged exposure to abnormal metabolic conditions, such as hyperglycemia, dyslipidemia, excess free fatty acids, and impaired mitochondrial energy production [4]. These conditions generate toxic metabolites and activate stress pathways that overwhelm cellular adaptive mechanisms [5]. Among the most important mediators of metabolic toxicity are oxidative stress and chronic inflammation, which act synergistically to exacerbate metabolic dysfunction and tissue injury.

Oxidative stress results from an imbalance between the production of reactive oxygen species and the capacity of antioxidant defense systems [6]. In parallel, chronic low-grade inflammation, often termed metaflammation, arises

from sustained metabolic stress and contributes to disease progression [7]. Despite their central roles, oxidative stress and inflammation are frequently considered secondary consequences rather than primary drivers of metabolic toxicity. This review highlights their integrated roles in chronic disease pathophysiology and emphasizes the need for a more holistic understanding of metabolic toxicity.

2. Metabolic Toxicity: Concept and Biological Basis

Metabolic toxicity arises when metabolic pathways that are normally tightly regulated become persistently dysregulated, overwhelming cellular adaptive capacity [8]. Under healthy physiological conditions, cells exhibit metabolic flexibility, enabling them to switch between substrates such as glucose and fatty acids in response to nutrient availability and energy demand [9]. Chronic exposure to adverse conditions including overnutrition, physical inactivity, aging, and genetic susceptibility, disrupts this flexibility. As a result, cells and tissues experience sustained elevations in circulating glucose, free fatty acids, and other metabolic intermediates that place continuous stress on metabolic systems [10].

At the cellular level, excess substrates saturate core metabolic pathways, including glycolysis, the tricarboxylic acid cycle, and fatty acid oxidation [11]. When these pathways operate beyond their optimal capacity, partially oxidized metabolites accumulate and exert toxic effects. These include advanced glycation end products formed under hyperglycemic conditions, lipid peroxides generated during abnormal lipid metabolism, and bioactive lipids such as ceramides that interfere with insulin signaling and promote apoptosis [12]. Together, these toxic intermediates disrupt membrane integrity, enzyme activity, and intracellular signaling networks. Metabolic toxicity therefore reflects not only an imbalance in energy supply and demand, but also a state of sustained biochemical stress that damages proteins, lipids, nucleic acids, and organelles [13].

A key characteristic of metabolic toxicity is its chronic and progressive nature [14]. While acute metabolic stress can activate compensatory mechanisms such as increased antioxidant defenses and stress-response signaling, prolonged metabolic overload leads to maladaptation[15]. Regulatory pathways become desensitized, mitochondrial efficiency declines, and stress-response systems remain persistently activated. Oxidative stress and inflammation are central features of this maladaptive state, acting as mechanistic links between metabolic excess and long-term cellular and tissue damage [16].

3. Oxidative Stress as a Driver of Metabolic Toxicity

3.1 Sources of Reactive Oxygen Species in Metabolic Dysregulation

Reactive oxygen species are continuously generated as by-products of aerobic metabolism, particularly during mitochondrial oxidative phosphorylation [17]. Under normal conditions, these species serve important signaling roles and are effectively controlled by endogenous antioxidant systems. However, chronic metabolic overload markedly enhances ROS production [18]. Excess glucose and fatty acids increase electron flux through the mitochondrial electron transport chain, promoting electron leakage and elevated superoxide formation [19]. Beyond mitochondria, several additional sources contribute to oxidative stress during metabolic dysregulation. These include activation of NADPH oxidases, uncoupling of nitric oxide synthase, and increased peroxisomal fatty acid oxidation [20]. Hyperglycemia also stimulates alternative metabolic pathways, such as the polyol, hexosamine, and protein kinase C pathways, all of which generate ROS as secondary products [21]. When the rate of ROS generation exceeds the buffering capacity of antioxidant systems, oxidative stress develops and initiates widespread cellular damage.

3.2 Oxidative Damage and Cellular Dysfunction

Oxidative stress drives metabolic toxicity through both direct macromolecular damage and disruption of signaling pathways [22]. ROS readily attack polyunsaturated fatty acids in membranes, triggering lipid peroxidation that compromises membrane fluidity and integrity. Oxidative modification of proteins alters enzyme kinetics, receptor binding, and structural stability, impairing essential cellular functions [23]. ROS-induced DNA damage activates repair mechanisms that consume cellular energy and, if persistent, may result in mutations, senescence, or apoptosis [24].

Crucially, oxidative stress interferes with metabolic signaling pathways. Oxidative modification of insulin receptors and downstream signaling components contributes to insulin resistance, a defining feature of metabolic disorders [25]. Damage to mitochondrial DNA further impairs oxidative phosphorylation, reducing ATP production and increasing ROS generation. This self-amplifying cycle reinforces metabolic inefficiency and establishes oxidative stress as a central driver of metabolic toxicity in chronic disease.

4. Chronic Inflammation and Metaflammation

4.1 Metabolic Triggers of Inflammation

Chronic inflammation associated with metabolic disease is distinct from classical acute inflammation that arises in response to infection or tissue injury [26]. This metabolically driven inflammatory state, often referred to as metaflammation, is characterized by low-grade but persistent activation of immune pathways in response to nutrient excess and metabolic imbalance [27]. Adipose tissue expansion during obesity plays a central role, as enlarged adipocytes become metabolically stressed and release chemokines that recruit immune cells, particularly macrophages. In parallel, ectopic lipid accumulation in non-adipose tissues such as liver and muscle promotes cellular stress and inflammatory signaling [28]. Alterations in gut microbiota composition further contribute by increasing intestinal permeability and systemic exposure to pro-inflammatory microbial products. Adipocytes and infiltrating immune cells secrete a range of pro-inflammatory mediators, including tumor necrosis factor-alpha, interleukin-6, and interleukin-1 beta [29]. These cytokines impair insulin signaling, enhance oxidative stress, and disrupt normal lipid and glucose metabolism [30]. In addition, elevated free fatty acids and modified lipoproteins act as danger-associated molecular patterns that activate innate immune receptors, thereby sustaining inflammatory responses [31].

4.2 Inflammatory Signaling Pathways

Several intracellular signaling pathways link metabolic stress to inflammation, notably nuclear factor kappa B, c-Jun N-terminal kinase, and inflammasome activation [32]. These pathways regulate inflammatory gene expression and are highly sensitive to redox changes. Oxidative stress amplifies inflammatory signaling, while activated immune cells generate additional reactive oxygen species [33]. This bidirectional interaction establishes a self-reinforcing cycle between inflammation and oxidative stress that perpetuates metabolic toxicity and accelerates chronic disease progression.

6. Metabolic Toxicity in Major Chronic Diseases

6.1 Diabetes and Metabolic Syndrome

In diabetes and metabolic syndrome, sustained hyperglycemia and dyslipidemia create a metabolic environment that strongly promotes oxidative stress and chronic inflammation [34]. Excess glucose enhances mitochondrial reactive oxygen species production and activates alternative metabolic pathways that generate additional oxidative stress. Simultaneously, elevated free fatty acids and inflammatory cytokines impair insulin signaling, leading to systemic insulin resistance [35]. Oxidative damage to pancreatic beta cells reduces insulin synthesis and secretion, while inflammatory mediators further compromise beta-cell survival. These intertwined processes contribute to the development of long-term diabetic complications, including neuropathy, nephropathy, and retinopathy, by damaging microvascular and neural tissues.

6.2 Cardiovascular Disease

Metabolic toxicity plays a central role in cardiovascular disease by promoting endothelial dysfunction and atherogenesis. Oxidative stress reduces nitric oxide bioavailability, impairing vascular relaxation and increasing vascular stiffness [36]. Inflammatory signaling within the vascular wall drives monocyte recruitment, foam cell formation, and plaque development. Dysregulated lipid metabolism leads to the accumulation and oxidation of low-density lipoproteins, further amplifying oxidative and inflammatory injury and increasing the risk of plaque instability and thrombosis.

6.3 Neurodegenerative Disorders

Neurodegenerative disorders are strongly influenced by metabolic toxicity due to the brain's high energy demand and vulnerability to redox imbalance [37]. Oxidative stress and inflammation disrupt neuronal signaling, promote synaptic loss, and facilitate protein misfolding and aggregation. Emerging evidence also implicates brain insulin resistance in accelerating neurodegenerative processes.

6.4 Chronic Kidney Disease

In chronic kidney disease, metabolic toxicity driven by uremic toxins, oxidative stress, and inflammation impairs mitochondrial function in renal cells, promotes fibrosis, and accelerates both renal and cardiovascular dysfunction [38].

CONCLUSION

Metabolic toxicity is a unifying mechanism underlying many chronic diseases, driven by sustained metabolic imbalance, oxidative stress, and chronic inflammation. Oxidative stress and inflammation are not merely secondary consequences but active participants in disease initiation and progression. Their interaction creates a self-perpetuating cycle that impairs mitochondrial function, disrupts cellular signaling, and accelerates tissue damage. A deeper understanding of metabolic toxicity through the lens of redox biology and inflammation provides a more integrated framework for chronic disease research and therapy. Addressing these interconnected

processes holds promise for more effective prevention and treatment strategies that move beyond symptom management toward restoration of metabolic and cellular homeostasis.

REFERENCES

1. Hacker K. The Burden of Chronic Disease. Mayo Clin Proc Innov Qual Outcomes. 2024 Jan 20;8(1):112-119. doi: 10.1016/j.mayocpiqo.2023.08.005. Erratum in: Mayo Clin Proc Innov Qual Outcomes. 2024 Dec 13;9(1):100588. doi: 10.1016/j.mayocpiqo.2024.11.005. PMID: 38304166; PMCID: PMC10830426.
2. Nieto MR, Saucedo-Delgado OA. The Cost of Chronicity: Analyzing the Direct Economic Burden of Chronic Diseases in the U.S. from 1996 to 2040. Economies. 2025; 13(11):316. https://doi.org/10.3390/economies13110316
3. Yang HY, Wei Y, Mao Q, Zhao LH. Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes. World J Diabetes. 2025 Dec 15;16(12):114395. doi: 10.4239/wjd.v16.i12.114395. PMID: 41480598; PMCID: PMC12754134.
4. Jiang J, Zhang H, Hussain M, Abdullah, Feng F, Guan R, Zhong H. Novel Approaches in Glucose and Lipid Metabolism Disorder Therapy: Targeting the Gut Microbiota–Bile Acid Axis. Biology. 2025; 14(7):802. https://doi.org/10.3390/biology14070802
5. Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, Nadal A, Palanza P, Panzica G, Sargis R, Vandenberg LN, Vom Saal F. Metabolism disrupting chemicals and metabolic disorders. Reprod Toxicol. 2017 Mar;68:3-33. doi: 10.1016/j.reprotox.2016.10.001. Epub 2016 Oct 17. PMID: 27760374; PMCID: PMC5365353.
6. Zayani Z, Matinahmadi A, Tavakolpournegari A, Bidooki SH. Exploring Stressors: Impact on Cellular Organelles and Implications for Cellular Functions. Stresses. 2025; 5(2):26. https://doi.org/10.3390/stresses5020026
7. Di Meo S, Reed TT, Venditti P, Victor VM. Role of ROS and RNS Sources in Physiological and Pathological Conditions. Oxid Med Cell Longev. 2016;2016:1245049. doi: 10.1155/2016/1245049. Epub 2016 Jul 12. PMID: 27478531; PMCID: PMC4960346.
8. Fulda S, Gorman AM, Hori O, Samali A. Cellular stress responses: cell survival and cell death. Int J Cell Biol. 2010;2010:214074. doi: 10.1155/2010/214074. Epub 2010 Feb 21. PMID: 20182529; PMCID: PMC2825543.
9. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020 Sep;20(9):516-531. doi: 10.1038/s41568-020-0273-y. Epub 2020 Jul 6. PMID: 32632251; PMCID: PMC8041116.
10. Robey RB, Weisz J, Kuemmerle NB, Salzberg AC, Berg A, Brown DG, Kubik L, Palorini R, Al-Mulla F, Al-Temaimi R, Colacci A, Mondello C, Raju J, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Amedei A, Hamid RA, Williams GP, Lowe L, Meyer J, Martin FL, Bisson WH, Chiaradonna F, Ryan EP. Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis? Carcinogenesis. 2015 Jun;36 Suppl 1(Suppl 1):S203-31. doi: 10.1093/carcin/bgv037. PMID: 26106140; PMCID: PMC4565609.
11. Mishra M, Nichols L, Dave AA, Pittman EH, Cheek JP, Caroland AJV, Lotwala P, Drummond J, Bridges CC. Molecular Mechanisms of Cellular Injury and Role of Toxic Heavy Metals in Chronic Kidney Disease. International Journal of Molecular Sciences. 2022; 23(19):11105. https://doi.org/10.3390/ijms231911105
12. Panov AV, Mayorov VI, Dikalov SI. Role of Fatty Acids β-Oxidation in the Metabolic Interactions Between Organs. International Journal of Molecular Sciences. 2024; 25(23):12740. https://doi.org/10.3390/ijms252312740
13. Khalid M, Petroianu G, Adem A. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules. 2022 Apr 4;12(4):542. doi: 10.3390/biom12040542. PMID: 35454131; PMCID: PMC9030615.
14. Mota KO, de Vasconcelos CML, Kirshenbaum LA, Dhalla NS. The Role of Advanced Glycation End-Products in the Pathophysiology and Pharmacotherapy of Cardiovascular Disease. International Journal of Molecular Sciences. 2025; 26(15):7311. https://doi.org/10.3390/ijms26157311
15. Chen CY, Zhang JQ, Li L, Guo MM, He YF, Dong YM, Meng H, Yi F. Advanced Glycation End Products in the Skin: Molecular Mechanisms, Methods of Measurement, and Inhibitory Pathways. Front Med (Lausanne). 2022 May 11;9:837222. doi: 10.3389/fmed.2022.837222. PMID: 35646963; PMCID: PMC9131003.

16. Zhang Y, Zhang Z, Tu C, Chen X, He R. Advanced Glycation End Products in Disease Development and Potential Interventions. Antioxidants. 2025; 14(4):492. https://doi.org/10.3390/antiox14040492
17. Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive Oxygen Species in Metabolic and Inflammatory Signaling. Circ Res. 2018 Mar 16;122(6):877-902. doi: 10.1161/CIRCRESAHA.117.311401. PMID: 29700084; PMCID: PMC5926825.
18. Zheng C, Chen J-P, Wang X-W, Li P. Reactive Oxygen Species in Plants: Metabolism, Signaling, and Oxidative Modifications. Antioxidants. 2025; 14(6):617. https://doi.org/10.3390/antiox14060617
19. de Almeida AJPO, de Oliveira JCPL, da Silva Pontes LV, de Souza Júnior JF, Gonçalves TAF, Dantas SH, de Almeida Feitosa MS, Silva AO, de Medeiros IA. ROS: Basic Concepts, Sources, Cellular Signaling, and its Implications in Aging Pathways. Oxid Med Cell Longev. 2022 Oct 19;2022:1225578. doi: 10.1155/2022/1225578. PMID: 36312897; PMCID: PMC9605829.
20. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. International Journal of Molecular Sciences. 2023; 24(9):7898. https://doi.org/10.3390/ijms24097898
21. Čolak E, Pap D. The role of oxidative stress in the development of obesity and obesity-related metabolic disorders. J Med Biochem. 2021 Jan 26;40(1):1-9. doi: 10.5937/jomb0-24652. PMID: 33584134; PMCID: PMC7857849.
22. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763. doi: 10.1155/2017/8416763. Epub 2017 Jul 27. PMID: 28819546; PMCID: PMC5551541.
23. Wall SB, Oh JY, Diers AR, Landar A. Oxidative modification of proteins: an emerging mechanism of cell signaling. Front Physiol. 2012 Sep 14;3:369. doi: 10.3389/fphys.2012.00369. PMID: 23049513; PMCID: PMC3442266.
24. Mahapatra C, Thakkar R, Kumar R. Modulatory Impact of Oxidative Stress on Action Potentials in Pathophysiological States: A Comprehensive Review. Antioxidants. 2024; 13(10):1172. https://doi.org/10.3390/antiox13101172
25. Cai Z, Yan LJ. Protein Oxidative Modifications: Beneficial Roles in Disease and Health. J Biochem Pharmacol Res. 2013 Mar;1(1):15-26. PMID: 23662248; PMCID: PMC3646577.
26. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017 Dec 14;9(6):7204-7218. doi: 10.18632/oncotarget.23208. PMID: 29467962; PMCID: PMC5805548.
27. Zotova N, Zhuravleva Y, Chereshnev V, Gusev E. Acute and Chronic Systemic Inflammation: Features and Differences in the Pathogenesis, and Integral Criteria for Verification and Differentiation. International Journal of Molecular Sciences. 2023; 24(2):1144. https://doi.org/10.3390/ijms24021144
28. Cao X, Wang N, Yang M, Zhang C. Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease. International Journal of Molecular Sciences. 2025; 26(14):6962. https://doi.org/10.3390/ijms26146962
29. Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, Gorecka D, Pyrzak B, Demkow U. Proinflammatory cytokines Il-6 and TNF-α and the development of inflammation in obese subjects. Eur J Med Res. 2010 Nov 4;15 Suppl 2(Suppl 2):120-2. doi: 10.1186/2047-783x-15-s2-120. PMID: 21147638; PMCID: PMC4360270.
30. López-Ortega O, Moreno-Corona NC, Cruz-Holguin VJ, Garcia-Gonzalez LD, Helguera-Repetto AC, Romero-Valdovinos M, Arevalo-Romero H, Cedillo-Barron L, León-Juárez M. The Immune Response in Adipocytes and Their Susceptibility to Infection: A Possible Relationship with Infectobesity. International Journal of Molecular Sciences. 2022; 23(11):6154. https://doi.org/10.3390/ijms23116154
31. Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017 Jul 1;113(9):1009-1023. doi: 10.1093/cvr/cvx108. PMID: 28838042; PMCID: PMC5852626.
32. Yung JHM, Giacca A. Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. Cells. 2020; 9(3):706. https://doi.org/10.3390/cells9030706
33. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015 Apr 15;6(3):456-80. doi: 10.4239/wjd.v6.i3.456. PMID: 25897356; PMCID: PMC4398902.
34. Caturano A, Rocco M, Tagliaferri G, Piacevole A, Nilo D, Di Lorenzo G, Iadicicco I, Donnarumma M, Galiero R, Acierno C, et al. Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From

Pathophysiology to Lifestyle Modifications. Antioxidants. 2025; 14(1):72. https://doi.org/10.3390/antiox14010072

35. Nicholas DA, Mbongue JC, Garcia-Pérez D, Sorensen D, Bennit HF, De Leon M, Langridge WHR. Exploring the Interplay between Fatty Acids, Inflammation, and Type 2 Diabetes. Immuno. 2024; 4(1):91-107. https://doi.org/10.3390/immuno4010006
36. van de Wouw J, Sorop O, van Drie RWA, Joles JA, Danser AHJ, Verhaar MC, Merkus D, Duncker DJ. Reduced nitric oxide bioavailability impairs myocardial oxygen balance during exercise in swine with multiple risk factors. Basic Res Cardiol. 2021 Aug 26;116(1):50. doi: 10.1007/s00395-021-00890-8. PMID: 34435256; PMCID: PMC8387273.
37. Rey F, Berardo C, Maghraby E, Mauri A, Messa L, Esposito L, Casili G, Ottolenghi S, Bonaventura E, Cuzzocrea S, Zuccotti G, Tonduti D, Esposito E, Paterniti I, Cereda C, Carelli S. Redox Imbalance in Neurological Disorders in Adults and Children. Antioxidants (Basel). 2023 Apr 20;12(4):965. doi: 10.3390/antiox12040965. PMID: 37107340; PMCID: PMC10135575.
38. Frąk W, Dąbek B, Balcerczyk-Lis M, Motor J, Radzioch E, Młynarska E, Rysz J, Franczyk B. Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease. Antioxidants (Basel). 2024 Jun 3;13(6):687. doi: 10.3390/antiox13060687. PMID: 38929126; PMCID: PMC11200916.

CITE AS: Zakaria Ali (2026). Metabolic Toxicity in Chronic Disease: The Overlooked Role of Oxidative Stress and Inflammation. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 7(2):60-65. https://doi.org/10.59298/NIJBAS/2026/7.2.6065